Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial

Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news